Dose–response of Pregabalin for diabetic peripheral neuropathy, postherpetic neuralgia, and fibromyalgia

According to literature, the exact therapeutic dose of Pregabalin is always a major issue among the different countries. Therefore, the results of this research demonstrated that the maximum recommended dose of Pregabalin is 300 mg/day for pDPN, 300–600 mg/day for PHN, and 300–450 mg/day for FM. 

The Pregabalin dose–response for pain, sleep quality, and Patient Global Impression of Change (PGIC) measures during painful diabetic peripheral neuropathy (pDPN), fibromyalgia (FM), and postherpetic neuralgia (PHN) is appropriate for physicians operating such patients. This investigation intended to illustrate the dose-response of Pregabalin for each manifestation and explain the incidence (onset), prevalence (onset/continuation), and resolution of adverse events (AEs) appearing throughout treatment.

The analysis involved fourteen placebo-controlled, fixed-dose Pregabalin trials. Participants exhibited mean baseline pain scores ≥six. The dose-response of Pregabalin for PGIC, sleep quality, and pain was investigated using a hyperbolic Emax dose-response model. Safety evaluations involved the onset and frequency of common AEs each week, and resolution during the first two months of therapy.

In all implications, the possibility of participants experiencing pain relief and improvements in sleep quality and PGIC enhanced in a dose-dependent fashion with rising doses. All indications showed the highest new incidences of somnolence and dizziness after one week of therapy, with some subsequent fresh reports at a given dose. Prevalence rates declined steadily following one week of treatment. In FM, new onset weight gain appeared 6–8 weeks after the treatment; prevalence rates usually risen then persisted constant over time. Several AEs resolved in month one except for weight gain.

The dose–response of Pregabalin for PGIC, pain, and sleep quality was illustrated, enlightening the advantage of obtaining the peak recommended dose of 300–450 mg/day for FM, 300–600 mg/day for PHN, and 300 mg/day for pDPN. Common AEs are commonly observed in one week of initiating treatment, with some subsequent fresh reports at a given dose. New onset weight gain appears following six weeks of therapy, reinforcing the requirement for routine monitoring of weight.